Johnson & Johnson stock jumped early Wednesday after the health care giant beat second-quarter forecasts and raised its outlook.

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...